Aberdeen Group’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $26.1M | Buy |
229,230
+12,989
| +6% | +$1.48M | 0.04% | 336 |
|
|
2025
Q1 | $22.7M | Buy |
216,241
+39,481
| +22% | +$4.15M | 0.04% | 361 |
|
|
2024
Q4 | $18.9M | Sell |
176,760
-72,509
| -29% | -$7.77M | 0.04% | 381 |
|
|
2024
Q3 | $24.9M | Sell |
249,269
-20,874
| -8% | -$2.09M | 0.05% | 342 |
|
|
2024
Q2 | $22.8M | Sell |
270,143
-11,413
| -4% | -$962K | 0.04% | 350 |
|
|
2024
Q1 | $20.6M | Sell |
281,556
-8,862
| -3% | -$648K | 0.04% | 400 |
|
|
2023
Q4 | $20.7M | Sell |
290,418
-29,711
| -9% | -$2.12M | 0.05% | 377 |
|
|
2023
Q3 | $19.2M | Sell |
320,129
-68,671
| -18% | -$4.11M | 0.05% | 327 |
|
|
2023
Q2 | $28M | Buy |
388,800
+107,093
| +38% | +$7.72M | 0.07% | 277 |
|
|
2023
Q1 | $20.7M | Sell |
281,707
-27,272
| -9% | -$2.01M | 0.05% | 342 |
|
|
2022
Q4 | $20.6M | Sell |
308,979
-400,122
| -56% | -$26.7M | 0.06% | 326 |
|
|
2022
Q3 | $38.1M | Buy |
709,101
+22,079
| +3% | +$1.19M | 0.11% | 203 |
|
|
2022
Q2 | $38.2M | Buy |
687,022
+150,012
| +28% | +$8.35M | 0.12% | 180 |
|
|
2022
Q1 | $37.7M | Sell |
537,010
-44,028
| -8% | -$3.09M | 0.1% | 220 |
|
|
2021
Q4 | $56M | Buy |
581,038
+6,904
| +1% | +$665K | 0.12% | 173 |
|
|
2021
Q3 | $49.9M | Sell |
574,134
-76,325
| -12% | -$6.63M | 0.11% | 189 |
|
|
2021
Q2 | $53.2M | Buy |
650,459
+370,764
| +133% | +$30.3M | 0.12% | 172 |
|
|
2021
Q1 | $26.6M | Sell |
279,695
-311,942
| -53% | -$29.7M | 0.06% | 285 |
|
|
2020
Q4 | $36.7M | Buy |
591,637
+275,859
| +87% | +$17.1M | 0.09% | 203 |
|
|
2020
Q3 | $18.8M | Buy |
+315,778
| New | +$18.8M | 0.05% | 309 |
|